Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company's segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases. Its Hematology products include ADVATE (Antihemophilic Factor (Recombinant)), ADYNOVATE/ADYNOVI (Antihemophilic Factor (Recombinant), PEGylated)), RIXUBIS (Coagulation Factor IX (Recombinant)), VONVENDI (von Willebrand factor (Recombinant)) and FEIBA (Anti-Inhibitor Coagulant Complex). Its Genetic Diseases products include CINRYZE (C1 esterase inhibitor (human)), FIRAZYR (icatibant), ELAPRASE (idursulfase), REPLAGAL (agalsidase alfa) and VPRIV (velaglucerase alfa).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Pharmaceuticals - NEC
- Sub-Industry: N/A
- Symbol: NASDAQ:SHPG
- CUSIP: N/A
- Web: www.shire.com
Average Prices:- 52 Week Range: $144.18 - $209.22
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 9.03
- P/E Growth: 0.00
Dividend:- Annual Dividend: $0.91
- Dividend Yield: 0.6%
Profitability:- Net Margins: 4.70%
- Return on Equity: 14.10%
- Return on Assets: 6.25%
Debt:- Debt-to-Equity Ratio: 0.59%
- Current Ratio: 0.96%
- Quick Ratio: 0.52%
Misc:
Frequently Asked Questions for Shire PLC (NASDAQ:SHPG)
What is Shire PLC's stock symbol?
Shire PLC trades on the NASDAQ under the ticker symbol "SHPG."
How often does Shire PLC pay dividends? What is the dividend yield for Shire PLC?
Shire PLC announced a semiannual dividend on Friday, August 11th. Investors of record on Friday, September 8th will be paid a dividend of $0.1527 per share on Friday, October 20th. This represents a yield of 0.21%. The ex-dividend date is Thursday, September 7th. View Shire PLC's Dividend History.
How were Shire PLC's earnings last quarter?
Shire PLC (NASDAQ:SHPG) posted its quarterly earnings results on Thursday, August, 3rd. The company reported $3.73 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $3.53 by $0.20. The firm had revenue of $3.75 billion for the quarter. Shire PLC had a return on equity of 14.10% and a net margin of 4.70%. The business's revenue was up 54.2% on a year-over-year basis. During the same period last year, the company earned $3.38 EPS. View Shire PLC's Earnings History.
When will Shire PLC make its next earnings announcement?
What guidance has Shire PLC issued on next quarter's earnings?
Shire PLC updated its FY17 earnings guidance on Thursday, August, 3rd. The company provided EPS guidance of $14.80-15.20 for the period, compared to the Thomson Reuters consensus estimate of $14.85. The company issued revenue guidance of $14.9-15.3 billion, compared to the consensus revenue estimate of $15.04 billion.
Where is Shire PLC's stock going? Where will Shire PLC's stock price be in 2017?
21 brokerages have issued 12-month target prices for Shire PLC's stock. Their predictions range from $159.00 to $325.00. On average, they expect Shire PLC's share price to reach $220.91 in the next year. View Analyst Ratings for Shire PLC.
What are analysts saying about Shire PLC stock?
Here are some recent quotes from research analysts about Shire PLC stock:
- 1. Cantor Fitzgerald analysts commented, "This morning, SHPG announced that the Marketing Authorization Application (MAA) for Lifitegrast has been validated by the UK as the Reference Member State involved in the Decentralized Procedure (DCP)." (8/15/2017)
- 2. According to Zacks Investment Research, "Shire reported encouraging Q2 results, beating estimates for both sales and earnings.The approval of Mydayis is likely to boost Shire’s ADHD segment dominance while strong performance of Vyvanse, Cinryze and Elaprase will continue to drive Shire’s top line. The label expansion of Cinryze in paediatrics and conditional approval of Natpara in Europe should continue to drive the top line going ahead. The hematology and immunology segment, acquired from Baxalta, gave a major boost to product sales. The approval of Xiidra has boosted the company’s ophthalmology space, acquiring roughly 23% of the total market by the end of Jun 2017. The Dyax acquisition has integrated well and Shire announced positive results from the phase III trial on lanadelumab in May 2017. However, the adult ADHD space is one of the largest and fastest growing segments of the market but is highly genericized. Moreover, shares have underperformed the industry." (8/8/2017)
- 3. Jefferies Group LLC analysts commented, "SHPG posted strong 4Q16 revs ($3.8B vs $3.7B JEF) and EPS ($3.37 vs $3.26 JEF) as nearly all core franchises performed well. In particular, GI and Orphan Diseases showed strength. As for legacy BXLT, Immunoglobulins and Hemophilia performed well while Inhibitors lagged. We like the setup for 2017. If mgt executes on core brands, the Xiidra launch, and the BXLT integration, we could envision share price outperformance, augmented by significant deleveraging." (2/17/2017)
Are investors shorting Shire PLC?
Shire PLC saw a increase in short interest in July. As of July 14th, there was short interest totalling 1,247,044 shares, an increase of 34.9% from the June 30th total of 924,373 shares. Based on an average daily volume of 1,330,164 shares, the days-to-cover ratio is currently 0.9 days.
Who are some of Shire PLC's key competitors?
Some companies that are related to Shire PLC include Eli Lilly and Company (LLY), Abbott Laboratories (ABT), Astrazeneca PLC (AZN), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Shire PLC (SHP), Teva Pharmaceutical Industries Limited (TEVA), Dr. Reddy's Laboratories Ltd (RDY), Patheon NV (PTHN), Valeant Pharmaceuticals International (VRX), Catalent (CTLT), Taro Pharmaceutical Industries (TARO), Akorn (AKRX), Opko Health (OPK), Hikma Pharmaceuticals Plc (HIK), BTG plc (BTG), Horizon Pharma PLC (HZNP) and Amicus Therapeutics (FOLD).
Who are Shire PLC's key executives?
Shire PLC's management team includes the folowing people:
- Flemming Ornskov M.D., Chief Executive Officer, Executive Director
- Jeffrey Poulton, Chief Financial Officer, Executive Director
- William Mordan, General Counsel, Company Secretary
- Perry Sternberg, Head - U.S. Commercial
- Kim Stratton, Head - International Commercial
- Philip J. Vickers, Head - Research and Development
- Matthew Walker, Head - Technical Operations
- Susan Saltzbart Kilsby, Independent Non-Executive Chairman of the Board
- Olivier Bohuon, Non-Executive Director
- Ian T. Clark, Non-Executive Director
Who owns Shire PLC stock?
Shire PLC's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Jennison Associates LLC (0.00%), Maverick Capital Ltd. (0.00%), Glenview Capital Management LLC (0.00%), FMR LLC (0.53%), Ameriprise Financial Inc. (0.51%) and Vanguard Group Inc. (0.49%). View Institutional Ownership Trends for Shire PLC.
Who sold Shire PLC stock? Who is selling Shire PLC stock?
Shire PLC's stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, FMR LLC, Voya Investment Management LLC, Arrowstreet Capital Limited Partnership, BlackRock Inc., Sphera Funds Management LTD., Sei Investments Co. and Capital Fund Management S.A.. View Insider Buying and Selling for Shire PLC.
Who bought Shire PLC stock? Who is buying Shire PLC stock?
Shire PLC's stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Glenview Capital Management LLC, Northern Trust Corp, OZ Management LP, Maverick Capital Ltd., Harding Loevner LP, Ameriprise Financial Inc. and Farallon Capital Management LLC. View Insider Buying and Selling for Shire PLC.
How do I buy Shire PLC stock?
Shares of Shire PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Shire PLC's stock price today?
One share of Shire PLC stock can currently be purchased for approximately $145.55.
MarketBeat Community Rating for Shire PLC (NASDAQ SHPG)MarketBeat's community ratings are surveys of what our community members think about Shire PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Shire PLC (NASDAQ:SHPG) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 7 Hold Ratings, 14 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.67) |
| Consensus Price Target: | $220.91 (51.78% upside) |
Analysts' Ratings History for Shire PLC (NASDAQ:SHPG)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 8/16/2017 | Evercore ISI | Initiated Coverage | Outperform -> Outperform | $196.00 | Medium |  |
| 8/15/2017 | Cantor Fitzgerald | Set Price Target | Buy | $222.00 | Low | |
| 8/11/2017 | Barclays PLC | Downgrade | Overweight -> Equal Weight | | Low | |
| 8/9/2017 | Jefferies Group LLC | Reiterated Rating | Hold | $216.00 -> $206.00 | Low | |
| 8/4/2017 | Royal Bank Of Canada | Set Price Target | Buy | $213.00 | Low | |
| 7/26/2017 | Piper Jaffray Companies | Set Price Target | Hold | $159.00 | Medium | |
| 7/17/2017 | BTIG Research | Reiterated Rating | Buy | $242.00 | Low | |
| 7/13/2017 | Sanford C. Bernstein | Reiterated Rating | Market Perform | $210.00 | Low | |
| 7/12/2017 | Stifel Nicolaus | Reiterated Rating | Buy | $245.00 | Low | |
| 7/6/2017 | HSBC Holdings plc | Upgrade | Reduce -> Hold | | Medium | |
| 6/1/2017 | Liberum Capital | Downgrade | Buy -> Hold | | Low | |
| 5/31/2017 | Cowen and Company | Reiterated Rating | Outperform | $325.00 | Low | |
| 4/17/2017 | Goldman Sachs Group, Inc. (The) | Boost Price Target | Overweight | $202.00 -> $214.00 | Low | |
| 2/17/2017 | Guggenheim | Reiterated Rating | Neutral | | N/A | |
| 12/2/2016 | Societe Generale | Initiated Coverage | Buy | | N/A | |
| 11/14/2016 | Leerink Swann | Set Price Target | Buy | $198.00 | N/A | |
| 11/7/2016 | J P Morgan Chase & Co | Reiterated Rating | Overweight | | N/A | |
| 11/3/2016 | Citigroup Inc. | Reiterated Rating | Buy | | N/A | |
| 11/2/2016 | Deutsche Bank AG | Reiterated Rating | Buy | | N/A | |
| 10/23/2016 | BNP Paribas | Reiterated Rating | Buy | | N/A | |
| 10/8/2016 | Shore Capital | Reiterated Rating | Buy | | N/A | |
| 6/3/2016 | Morgan Stanley | Reiterated Rating | Overweight | | N/A | |
| 5/23/2016 | Bryan, Garnier & Co | Initiated Coverage | Buy | | N/A | |
| 3/30/2016 | Bank of America Corporation | Reiterated Rating | Buy | | N/A | |
| 2/13/2016 | Northland Securities | Reiterated Rating | Buy | | N/A | |
| 2/8/2016 | Susquehanna Bancshares Inc | Lower Price Target | Positive | $280.00 -> $220.00 | N/A | |
| 1/18/2016 | Credit Suisse Group | Upgrade | Buy | | N/A | |
| 10/21/2015 | William Blair | Reiterated Rating | Outperform | $276.00 | N/A | |
(Data available from 8/19/2015 forward)
Earnings History for Shire PLC (NASDAQ:SHPG)Earnings History by Quarter for Shire PLC (NASDAQ SHPG)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/7/2017 | | | | | | | | |
| 8/3/2017 | 6/30/2017 | $3.53 | $3.73 | | $3.75 billion | View | Listen | |
| 5/2/2017 | Q1 17 | $3.22 | $3.63 | | $3.57 billion | View | Listen | |
| 2/16/2017 | Q416 | $3.24 | $3.37 | $3.78 billion | $3.81 billion | View | N/A | |
| 11/1/2016 | Q316 | $3.21 | $3.17 | $3.57 billion | $3.45 billion | View | N/A | |
| 8/2/2016 | Q216 | $3.03 | $3.38 | $2.28 billion | $2.43 million | View | N/A | |
| 4/29/2016 | Q1 | $3.05 | $3.19 | $1.71 billion | $1.71 billion | View | Listen | |
| 2/11/2016 | Q415 | $2.89 | $2.97 | $1.69 million | $1.72 billion | View | Listen | |
| 10/23/2015 | Q315 | $2.87 | $3.24 | $1.63 billion | $1.58 billion | View | Listen | |
| 7/23/2015 | Q215 | $2.81 | $2.63 | $1.59 billion | $1.56 billion | View | Listen | |
| 4/30/2015 | Q115 | $2.56 | $2.84 | $1.47 billion | $1.49 billion | View | N/A | |
| 2/12/2015 | Q115 | $2.68 | $2.63 | $1.53 billion | $1.58 billion | View | N/A | |
| 10/24/2014 | Q314 | $2.47 | $2.93 | $1.46 billion | $1.55 billion | View | Listen | |
| 7/18/2014 | Q214 | $2.45 | $2.67 | $1.45 billion | $1.50 billion | View | N/A | |
| 5/1/2014 | Q114 | $2.22 | $2.36 | $1.38 billion | $1.35 billion | View | N/A | |
| 2/13/2014 | Q413 | $2.02 | $2.26 | $1.28 billion | $1.33 billion | View | N/A | |
| 10/24/2013 | Q213 | $1.65 | $1.77 | $1.23 billion | $1.24 billion | View | N/A | |
| 7/25/2013 | | $1.60 | $1.79 | $1.21 billion | $1.28 billion | View | N/A | |
| 5/2/2013 | Q113 | $1.56 | $1.63 | $1.21 billion | $1.16 billion | View | N/A | |
| 2/14/2013 | Q412 | $1.58 | $1.58 | $1.20 billion | $1.20 billion | View | N/A | |
| 10/25/2012 | | $1.47 | $1.36 | | | View | N/A | |
| 8/1/2012 | | $1.52 | $1.68 | | | View | N/A | |
| 4/26/2012 | | $0.52 | $1.24 | | | View | N/A | |
| 2/9/2012 | | $0.48 | $0.44 | | | View | N/A | |
| 10/28/2011 | | $1.31 | $1.28 | | | View | N/A | |
| 7/28/2011 | | $1.24 | $1.33 | | | View | N/A | |
| 4/28/2011 | | $1.18 | $1.23 | | | View | N/A | |
| 2/10/2011 | | $1.04 | $1.03 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Shire PLC (NASDAQ:SHPG)2017 EPS Consensus Estimate: $14.74
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 4 | $3.22 | $3.36 | $3.31 |
| Q2 2017 | 4 | $3.53 | $3.69 | $3.61 |
| Q3 2017 | 4 | $3.59 | $3.89 | $3.73 |
| Q4 2017 | 4 | $3.75 | $4.26 | $4.09 |
(Data provided by Zacks Investment Research)
Current Dividend Information for Shire PLC (NASDAQ:SHPG)| Next Dividend: | 10/20/2017 |
| Annual Dividend: | $0.91 |
| Dividend Yield: | 0.63% |
| Payout Ratio: | 40.63% (Trailing 12 Months of Earnings)
6.09% (Based on This Year's Estimates)
5.65% (Based on Next Year's Estimates)
|
Dividend History by Quarter for Shire PLC (NASDAQ SHPG)| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 8/11/2017 | semiannual | $0.15 | 0.21% | 9/7/2017 | 9/8/2017 | 10/20/2017 |
| 2/24/2017 | | $0.77 | | 3/8/2017 | 3/10/2017 | 4/25/2017 |
| 8/5/2016 | | $0.14 | | 9/7/2016 | 9/9/2016 | 10/7/2016 |
| 2/11/2016 | | $0.67 | | 3/9/2016 | 3/11/2016 | 4/12/2016 |
| 7/23/2015 | | $0.13 | | 9/2/2015 | 9/4/2015 | 10/2/2015 |
| 2/23/2015 | semiannual | $0.57 | 0.48% | 3/11/2015 | 3/13/2015 | 4/14/2015 |
| 8/4/2014 | semiannual | $0.11 | 0.09% | 9/3/2014 | 9/5/2014 | 10/3/2014 |
| 2/20/2014 | semiannual | $0.51 | 0.61% | 3/5/2014 | 3/7/2014 | 4/8/2014 |
| 7/29/2013 | semiannual | $0.09 | 0.16% | 9/4/2013 | 9/6/2013 | 10/3/2013 |
| 2/19/2013 | semiannual | $0.44 | 0.92% | 3/6/2013 | 3/8/2013 | 4/9/2013 |
(Data available from 1/1/2013 forward)
Insider Trading History for Shire PLC (NASDAQ:SHPG)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Shire PLC (NASDAQ:SHPG)
Latest Headlines for Shire PLC (NASDAQ:SHPG)
| Source: |
|
| Date | Headline |
|---|
 | Shire PLC (SHPG) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - August 18 at 5:26 PM |
 | Shire Files Marketing Application for Lifitegrast in Europe - Nasdaq ... - Nasdaq
www.nasdaq.com - August 17 at 4:37 PM |
| Shire PLC (SHPG) Research Coverage Started at Evercore ISI
www.americanbankingnews.com - August 16 at 6:26 PM |
 | Shire submits marketing application in Europe for lifitegrast for dry eye disease
seekingalpha.com - August 16 at 7:29 AM |
 | Shire announces submission of lifitegrast Marketing Authorization Application for treatment of dry eye disease in Europe
finance.yahoo.com - August 16 at 7:29 AM |
| Shire PLC (SHPG) Earns "Buy" Rating from Cantor Fitzgerald
www.americanbankingnews.com - August 15 at 11:16 AM |
| Shire applies for European approval of potential blockbuster eye drop
finance.yahoo.com - August 15 at 6:56 AM |
| Shire PLC (NASDAQ:SHPG) Plans $0.15 Semiannual Dividend
www.americanbankingnews.com - August 11 at 6:06 PM |
| Shire PLC (NASDAQ:SHPG) Lowered to Equal Weight at Barclays PLC
www.americanbankingnews.com - August 11 at 4:04 PM |
| Shire PLC (NASDAQ:SHPG) to Post FY2017 Earnings of $15.04 Per Share, SunTrust Banks Forecasts
www.americanbankingnews.com - August 10 at 9:32 AM |
| Shire Becomes Oversold (SHPG) - Nasdaq
www.nasdaq.com - August 10 at 7:50 AM |
| Jefferies Group LLC Reaffirms "Hold" Rating for Shire PLC (SHPG)
www.americanbankingnews.com - August 9 at 3:26 PM |
| FY2017 Earnings Forecast for Shire PLC (SHPG) Issued By Cantor Fitzgerald
www.americanbankingnews.com - August 9 at 8:36 AM |
| SunTrust Banks Analysts Reduce Earnings Estimates for Shire PLC (SHPG)
www.americanbankingnews.com - August 9 at 7:26 AM |
| Shire PLC to Post Q4 2017 Earnings of $3.75 Per Share, William Blair Forecasts (SHPG)
www.americanbankingnews.com - August 7 at 8:02 AM |
| Shire PLC (SHPG) Forecasted to Earn Q2 2017 Earnings of $3.62 Per Share
www.americanbankingnews.com - August 7 at 7:04 AM |
| Shire PLC (SHPG) Given a $213.00 Price Target by Royal Bank Of Canada Analysts
www.americanbankingnews.com - August 6 at 7:08 PM |
| Shire PLC (NASDAQ:SHPG) Downgraded to "Strong Sell" at BidaskClub
www.americanbankingnews.com - August 5 at 11:04 AM |
| Why Corporate Spinoffs For Shire And Valeant Make Sense - Seeking Alpha
seekingalpha.com - August 5 at 7:00 AM |
| Shire Q2/2017: Market Reaction Makes No Sense - Seeking Alpha
seekingalpha.com - August 5 at 7:00 AM |
| Shire PLC (SHPG) Releases Earnings Results, Beats Expectations By $0.20 EPS
www.americanbankingnews.com - August 5 at 12:22 AM |
| Brokers Set Expectations for Shire PLC's Q4 2017 Earnings (NASDAQ:SHPG)
www.americanbankingnews.com - August 4 at 2:38 PM |
| Earnings Reaction History: Shire plc, 33.3% Follow-Through Indicator, 2.9% Sensitive - Nasdaq
www.nasdaq.com - August 4 at 8:10 AM |
| No Room For Neuroscience In New-Look Shire - Seeking Alpha
seekingalpha.com - August 4 at 8:10 AM |
| Shire Surges on Baxalta Synergies and Strong Earnings Momentum
finance.yahoo.com - August 4 at 8:10 AM |
| Shire tops Street 2Q forecasts
finance.yahoo.com - August 4 at 8:10 AM |
| [$$] Shire Mulls Spinning-off or Selling Neuroscience Unit
finance.yahoo.com - August 4 at 8:10 AM |
| Shire Acq Inv Ireland Designated Activity Co -- Moody's: Shire's evaluation of neuroscience franchise credit negative
finance.yahoo.com - August 4 at 8:10 AM |
| [$$] Lombard: Impatient Shire boss waits for market to catch up
finance.yahoo.com - August 4 at 8:10 AM |
| Shire's ADHD Spinoff Idea Is Shaky
finance.yahoo.com - August 4 at 8:10 AM |
| Shire plc : Half-yearly report
finance.yahoo.com - August 4 at 8:10 AM |
| Shire PLC (NASDAQ:SHPG) Releases FY17 Earnings Guidance
www.americanbankingnews.com - August 3 at 9:26 AM |
| Zacks: Analysts Expect Shire PLC (NASDAQ:SHPG) Will Announce Quarterly Sales of $3.73 Billion
www.americanbankingnews.com - August 3 at 7:28 AM |
| Arrow Financial Corp Buys iShares MSCI All Country Asia ex Japan Index Fund, Sherwin-Williams ...
www.nasdaq.com - August 2 at 4:26 PM |
| Shire PLC (NASDAQ:SHPG) Short Interest Update
www.americanbankingnews.com - July 29 at 7:10 AM |
 | Shire Stock Rising on Takeover Talks - TheStreet.com
www.thestreet.com - July 28 at 7:55 AM |
| Shire PLC (NASDAQ:SHPG) to Release Earnings on Thursday
www.americanbankingnews.com - July 27 at 3:48 PM |
 | Shire plc (SHPG) Said Back in Play - Standard - StreetInsider.com
www.streetinsider.com - July 27 at 7:24 AM |
| Shire Stock Rising on Takeover Talks
finance.yahoo.com - July 27 at 7:24 AM |
 | Drug Makers Stock Performance Review -- Alliqua BioMedical, Aerie Pharma, Shire, and Heron Therapeutics - PR Newswire (press release)
www.prnewswire.com - July 26 at 7:32 AM |
| Don't Lose The Faith In Shire - Seeking Alpha
seekingalpha.com - July 26 at 7:32 AM |
| Gap In Perceived and Actual Rates Of Prescription Stimulant Misuse, Abuse and Diversion Found Among College Students
finance.yahoo.com - July 26 at 7:32 AM |
| Shire PLC (SHPG) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - July 24 at 5:20 PM |
| Shire PLC (NASDAQ:SHPG) Expected to Earn FY2017 Earnings of $14.63 Per Share
www.americanbankingnews.com - July 20 at 9:53 AM |
| Exane Asset Management Buys Monsanto Co, Biogen Inc, Qiagen NV, Sells Citigroup Inc, W R Grace, ...
www.nasdaq.com - July 20 at 7:42 AM |
| FY2018 EPS Estimates for Shire PLC (NASDAQ:SHPG) Decreased by Analyst
www.americanbankingnews.com - July 19 at 1:56 PM |
| William Blair Equities Analysts Lower Earnings Estimates for Shire PLC (SHPG)
www.americanbankingnews.com - July 19 at 9:57 AM |
| Marinus Pharmaceuticals (MRNS) and Shire PLC (NASDAQ:SHPG) Critical Survey
www.americanbankingnews.com - July 18 at 10:19 PM |
| Q2 2017 EPS Estimates for Shire PLC Decreased by SunTrust Banks (NASDAQ:SHPG)
www.americanbankingnews.com - July 18 at 9:35 AM |
| Shire Expands Broad Monoclonal Antibody Research Platform, Enters License Agreement for Novimmune Bi-specific ... - Nasdaq
www.nasdaq.com - July 18 at 8:08 AM |
Shire PLC (SHPG) Chart for Saturday, August, 19, 2017
